Zepto Life Technology has been selected as one of six semi-finalists for the prestigious 2020 AACC Disruptive Technology Award. Zepto aims to revolutionize diagnostics by replacing traditional blood cultures with a rapid, point-of-care molecular diagnostic platform that identifies pathogen cell-free DNA directly from plasma.
Zepto’s innovative technology utilizes Giant Magnetoresistance (GMR), combining microarray and melting curve techniques to deliver unparalleled diagnostic accuracy. At the presentation, Zepto showcased its ability to detect multiple invasive fungal infections using GMR technology, which enables multiplexing to identify various pathogens simultaneously. The assay example highlighted the detection of nine fungal strains that account for 95% of fungal infections in the U.S.
About AACC’s Disruptive Technology Award Competition
AACC’s Disruptive Technology Award competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing.
To learn more about AACC’s Disruptive Technology Award: https://meeting.aacc.org/conference-program/disruptive-technology-award
About Zepto Life Technology
Founded in 2014, Zepto Life Technology is a privately held company based in St. Paul, Minnesota. We are at the forefront of developing groundbreaking products that can detect invasive fungal infections using cell-free DNA found in blood. Our cutting-edge detection technology, Giant Magneto Resistance (GMR), is renowned for its high sensitivity and specificity. This Nobel Prize-winning technology from 2007 enables us to detect multiple infections accurately without compromising specificity.
In collaboration with Mayo Clinic, Zepto Life Technology is committed to advancing healthcare by providing precise and reliable diagnostic solutions.